ArticleBMC psychiatry2026
Body dysmorphic disorder among patients who have follow-up in the dermatology unit in Ethiopia: a cross-sectional study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBody dysmorphic disorder is a common mental disorder among dermatology patients and causes significant psychological distress. However, its screening is usually missed in clinical settings. Moreover, limited studies have been conducted in sub-Saharan Africa, including Ethiopia. Hence, this study aimed to assess the magnitude and associated factors of body dysmorphic symptoms among dermatology patients in an Ethiopian setting.
objectiveThe objective of this study was to assess the magnitude and associated factors of body dysmorphic disorder among dermatology patients during follow-up.
methodsA hospital-based cross-sectional study was conducted on a total of 404 study participants from September 1 to 30, 2023. Systematic random sampling was utilized to recruit participants. The Body Dysmorphic Disorder Questionnaire (BDDQ), a screening tool based on DSM-IV criteria, was used to assess body dysmorphic disorders. Multivariable regression analysis was performed to evaluate the strength of associations. A P-value less than 0.05 indicated statistical significance.
resultsA total of 399 patients participated in the study, for a response rate of 98.8%. The prevalence of body dysmorphic disorder was 70(17.5%) with a 95% CI: (13.8, 21.30). Female sex (AOR = 2.81, 95% (CI = 1.30-6.08), low family income (AOR = 2.26, 95% (1.09-4.69), sexual abuse (AOR = 3.65, 95% (CI = 1.45-9.15), physical abuse (AOR = 2.85, 95% (CI = 1.10-7.39), low self-esteem (AOR = 3.31, 95% (CI = 1.14-9.61), depression (AOR = 2.64; 95% (CI = 1.26-5.53), anxiety (AOR = 2.23, 95% (CI = 1.07-4.63), stress (AOR = 2.76, 95% (CI = 1.34-5.684) and perceived stigma (AOR = 2.46, 95% (CI = 1.20-5.02) were factors associated with body dysmorphic disorder.
conclusionThe prevalence of body dysmorphic disorder among dermatology patients was high and positively associated with symptoms such as depression, anxiety, stress, sexual and physical abuse, low self-esteem, and perceived stigma. Therefore, skin health care providers are recommended to screen the patients for body dysmorphic disorder among dermatology patients and facilitate referral to mental health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.